Collectively, our data suggest that EZH2 is a member of the network of cancer metabolism and that EZH2 deficiency upregulates GLS expression and blocks the glucose-deprivation-induced inhibition of GLS transcription in glucose-sensitive cells. The gene discussed is EZH2; the disease is cancer.